Faeth Therapeutics stock falls 17.10 percent in one month
Published on 10/01/2026 at 08:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Faeth Therapeutics stock fell 17.10 percent over the month through September 29, 2026, when the Nasdaq close stood at USD 28.07. The company appointed cancer biologist Karen Vousden to its board effective September 11, 2026, while its lead program PIKTOR moves toward Phase 2 data in endometrial cancer.
Board change precedes clinical data
According to Business Wire on September 17, 2026, Faeth announced Vousden's appointment after she had served as a scientific co-founder and adviser. Her board term runs alongside the company's development of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib.
The program targets the PI3K, AKT and mTOR pathway in endometrial and breast cancer. That focus gives the board appointment a direct link to the company's central clinical strategy, rather than representing a purely administrative change.
October event sets next checkpoint
Business Wire also reports that Faeth will host a virtual key opinion leader event on October 6, 2026, at 10:00 a.m. ET. The session is scheduled to cover PIKTOR, the PI3K, AKT and mTOR pathway, and the ongoing Phase 2 program.
For investors, the date creates a defined near-term information point. The event is not a clinical readout, but management plans to discuss the treatment approach and development work behind the lead program.
Losses keep financing central
Faeth reported a USD 186.0 million net loss for the six months ended June 30, 2026, in the filing summary published by Stock Titan. The same summary describes a USD 200.0 million private placement and identifies the June 30 reporting period.
The company was formerly known as Sensei Biotherapeutics and now trades as Faeth Therapeutics under ticker FTH on Nasdaq, according to MarketScreener. The identity change matters because older SNSE references describe the predecessor company, while current disclosures center on Faeth and PIKTOR.
Nasdaq close and market value
Faeth's market capitalization was USD 731.7 million as of September 30, 2026, while its Nasdaq close was USD 28.07 on September 29, 2026. The stock's 17.10 percent monthly decline and the six-month USD 186.0 million loss leave the October 6 event as a concrete test of how clearly management can frame the clinical and financing path.
Faeth Therapeutics stock facts
- Company: Faeth Therapeutics, Inc.
- Ticker: FTH
- Primary exchange: Nasdaq
- Market capitalization: USD 731.7 million as of September 30, 2026
- Sector / Industry: Healthcare / Biotechnology
- Next event: October 6, 2026
